Market Overview:
The global drugs and diagnostics for hematological disorders market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of hematological disorders, rising demand for point-of-care testing, and technological advancements in drugs and diagnostics for hematological disorders. The global drugs and diagnostics for hematological disorders market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into analyzers and reagents. The analyzers segment is further subsegmented into flow cytometers, immunoassays, spectrophotometers & nephelometers; while reagents are further subsegmented into antibodies & antigens (immunology), enzymes (biochemistry), molecular probes (molecular biology), erythrocyte sedimentation rate (ESR) Westergren tubes). On the basis of application, the market is divided into academic & research institutes; point-of-care testing; patient self-testing; biopharmaceutical industries; hospitals; clinical laboratories.
Product Definition:
Drugs and diagnostics for hematological disorders are important because they can help to identify and treat the causes of these disorders.
Analyzers:
Analzymes are enzymes that catalyze the chemical reaction between the substrate and the product. They are used in various applications such as drug discovery, biotechnology, clinical chemistry, molecular biology and other hematology related tests. The market for analyzers is expected to witness lucrative growth over the forecast period owing to factors such as increasing prevalence of blood disorders coupled with growing demand for rapid diagnostic techniques leading to early treatment of diseases.
Reagents:
Reagents are chemicals that help in detecting or identifying a particular substance. Reagents are used in hematology for various applications such as blood count analysis, hemoglobinopathies testing, and identification of chromosomal aberrations.
Application Insights:
The academic and research institutes segment dominated the industry in 2017, accounting for a revenue share of more than 60%. This is attributed to factors such as an increase in R&D activities pertaining to hematology. For instance, according to the American Society of Hematology (ASH) 2018 conference proceedings, there were over 1,000 posters related to various aspects of blood disorders at this year¢â‚¬â„¢s event.
Furthermore, increasing government funding for clinical trials pertaining to hemato-oncology is also expected drive growth during the forecast period. For instance, under COVID19 (HIV), a clinical trial by Merck will enroll approximately 2,400 healthy volunteers and 200 participants with HIV who are 18 years or older from around the world.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, advanced healthcare infrastructure, and high adoption rate for advanced diagnostics are some factors contributing to the growth of this regional market. Moreover, increasing prevalence of blood disorders such as anemias and leukemias is also expected to drive the demand for these products over the forecast period. For instance, according to data published by American Cancer Society in 2018 regarding incidence rates of cancer in North America; it was observed that there were 1,735 new cases of leukemia per million individuals (age 13 & above) in Canada during 2015-2016.
Asia Pacific is anticipated to be one of fastest growing regions due to rising disposable income levels and improving healthcare facilities especially in developing countries such as India & China along with other Southeast Asian countries.
Growth Factors:
- Increasing incidence of hematological disorders: The global incidence of hematological disorders is increasing at a rapid pace. This is primarily attributed to the changing lifestyle and dietary habits, growing pollution levels, and other environmental factors. This is expected to drive the demand for drugs and diagnostics for hematological disorders in the coming years.
- Growing awareness about hematological disorders: There is a growing awareness among people about various types of hematological disorders and their symptoms. This has led to an increase in the number of people seeking early diagnosis and treatment for these conditions. This is expected to boost the growth of the drugs and diagnostics for hemato-logical disorder market in the coming years.
- Technologically advanced products: The manufacturers are introducing technologically advanced products that can diagnose various types of blood diseases at an early stage with greater accuracy than ever before possible using traditional methods such as microscopy or flow cytometry techniques etcetera .This trend would fuel market demand over forecast period . 4 Emerging economies offer potential growth opportunities: A large number of emerging economies such as China, India, Brazil, Mexico etc., offer immense potential for growth in terms of sales revenue generated from drugs and diagnostics for hemato-logical disorder market segments over forecast period owing to rising income levels coupled with increasing prevalence rates Hematology diagnostic equipment are also witnessing increased adoption due rising incidences rate across globe , this will further fuel overall diagnostic industry revenue during forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Drugs and Diagnostics for Hematological Disorders Market Research Report
By Type
Analyzers, Reagents
By Application
Academic and Research Institute, Point of Care Testing, Patient Self-testing, Biopharmaceutical Industries, Hospitals, Clinical Laboratories
By Companies
Abbot, Pfizer, Amgen, Beckman Coulter, Mindray, Roche, Biorad, Eli Lilly, Sysmex, Bristol-Myers, Siemens, Horbia, Nihon Kohden
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Drugs and Diagnostics for Hematological Disorders Market Report Segments:
The global Drugs and Diagnostics for Hematological Disorders market is segmented on the basis of:
Types
Analyzers, Reagents
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Academic and Research Institute, Point of Care Testing, Patient Self-testing, Biopharmaceutical Industries, Hospitals, Clinical Laboratories
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbot
- Pfizer
- Amgen
- Beckman Coulter
- Mindray
- Roche
- Biorad
- Eli Lilly
- Sysmex
- Bristol-Myers
- Siemens
- Horbia
- Nihon Kohden
Highlights of The Drugs and Diagnostics for Hematological Disorders Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Analyzers
- Reagents
- By Application:
- Academic and Research Institute
- Point of Care Testing
- Patient Self-testing
- Biopharmaceutical Industries
- Hospitals
- Clinical Laboratories
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drugs and Diagnostics for Hematological Disorders Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Drugs and diagnostics for hematological disorders are medications and tests used to diagnose or monitor blood diseases.
Some of the major players in the drugs and diagnostics for hematological disorders market are Abbot, Pfizer, Amgen, Beckman Coulter, Mindray, Roche, Biorad, Eli Lilly, Sysmex, Bristol-Myers, Siemens, Horbia, Nihon Kohden.
The drugs and diagnostics for hematological disorders market is expected to grow at a compound annual growth rate of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Drugs and Diagnostics for Hematological Disorders Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Drugs and Diagnostics for Hematological Disorders Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Drugs and Diagnostics for Hematological Disorders Market - Supply Chain
4.5. Global Drugs and Diagnostics for Hematological Disorders Market Forecast
4.5.1. Drugs and Diagnostics for Hematological Disorders Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Drugs and Diagnostics for Hematological Disorders Market Size (000 Units) and Y-o-Y Growth
4.5.3. Drugs and Diagnostics for Hematological Disorders Market Absolute $ Opportunity
5. Global Drugs and Diagnostics for Hematological Disorders Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Type
5.3.1. Analyzers
5.3.2. Reagents
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Drugs and Diagnostics for Hematological Disorders Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Application
6.3.1. Academic and Research Institute
6.3.2. Point of Care Testing
6.3.3. Patient Self-testing
6.3.4. Biopharmaceutical Industries
6.3.5. Hospitals
6.3.6. Clinical Laboratories
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Drugs and Diagnostics for Hematological Disorders Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Drugs and Diagnostics for Hematological Disorders Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Drugs and Diagnostics for Hematological Disorders Demand Share Forecast, 2019-2029
9. North America Drugs and Diagnostics for Hematological Disorders Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Application
9.4.1. Academic and Research Institute
9.4.2. Point of Care Testing
9.4.3. Patient Self-testing
9.4.4. Biopharmaceutical Industries
9.4.5. Hospitals
9.4.6. Clinical Laboratories
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Type
9.7.1. Analyzers
9.7.2. Reagents
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Drugs and Diagnostics for Hematological Disorders Demand Share Forecast, 2019-2029
10. Latin America Drugs and Diagnostics for Hematological Disorders Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Application
10.4.1. Academic and Research Institute
10.4.2. Point of Care Testing
10.4.3. Patient Self-testing
10.4.4. Biopharmaceutical Industries
10.4.5. Hospitals
10.4.6. Clinical Laboratories
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Type
10.7.1. Analyzers
10.7.2. Reagents
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Drugs and Diagnostics for Hematological Disorders Demand Share Forecast, 2019-2029
11. Europe Drugs and Diagnostics for Hematological Disorders Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Application
11.4.1. Academic and Research Institute
11.4.2. Point of Care Testing
11.4.3. Patient Self-testing
11.4.4. Biopharmaceutical Industries
11.4.5. Hospitals
11.4.6. Clinical Laboratories
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Type
11.7.1. Analyzers
11.7.2. Reagents
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Drugs and Diagnostics for Hematological Disorders Demand Share, 2019-2029
12. Asia Pacific Drugs and Diagnostics for Hematological Disorders Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Application
12.4.1. Academic and Research Institute
12.4.2. Point of Care Testing
12.4.3. Patient Self-testing
12.4.4. Biopharmaceutical Industries
12.4.5. Hospitals
12.4.6. Clinical Laboratories
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Type
12.7.1. Analyzers
12.7.2. Reagents
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Drugs and Diagnostics for Hematological Disorders Demand Share, 2019-2029
13. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Application
13.4.1. Academic and Research Institute
13.4.2. Point of Care Testing
13.4.3. Patient Self-testing
13.4.4. Biopharmaceutical Industries
13.4.5. Hospitals
13.4.6. Clinical Laboratories
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Market Size and Volume Forecast by Type
13.7.1. Analyzers
13.7.2. Reagents
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Drugs and Diagnostics for Hematological Disorders Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Drugs and Diagnostics for Hematological Disorders Market: Market Share Analysis
14.2. Drugs and Diagnostics for Hematological Disorders Distributors and Customers
14.3. Drugs and Diagnostics for Hematological Disorders Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbot
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Amgen
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Beckman Coulter
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Mindray
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Roche
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Biorad
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eli Lilly
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Sysmex
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Bristol-Myers
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Siemens
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Horbia
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Nihon Kohden
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
